SWOG-8814 study
The retrospective analysis of the SWOG-8814 trial, in which HR+, node-positive, postmenopausal patients were randomised to chemoendocrine therapy vs endocrine therapy alone, established that the Recurrence Score® result is predictive of chemotherapy benefit in node-positive patients
The Recurrence Score result was a predictive factor of chemotherapy benefit for disease-free survival (p-value for interaction = 0.029), overall survival and breast cancer-specific survival in the first five years.
